Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Insulin-Like Growth Factor Binding Protein 3 Promoter Variant (Rs2854744) Is Associated With Nonalcoholic Fatty Liver Disease Publisher Pubmed



Mahmoudi T1 ; Nouri S2 ; Zarei F3 ; Najafabadi ZN4 ; Sanei M5 ; Sayedsalehi S1 ; Rezamand G6, 7 ; Asadi A8 ; Dabiri R9 ; Nobakht H9 ; Farahani H10 ; Tabaeian SP6, 7 ; Zali MR1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Department of Radiology, School of Medicine, Arak University of Medical Sciences, Arak, Iran
  3. 3. Department of Pharmaceutical Sciences, Universita degli Studi di Milano, Milan, Italy
  4. 4. School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Faculty of Medicine, Mashhad Branch, Islamic Azad University, Mashhad, Iran
  6. 6. Department of Internal Medicine, School of Medicine, Iran Universitof Medical Sciences, Tehran, Iran
  7. 7. Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran
  8. 8. Department of Biology, Faculty of Science, University of Mohaghegh Ardabili, Ardabil, Iran
  9. 9. Internal Medicine Department, Semnan University of Medical Sciences, Semnan, Iran
  10. 10. Department of Physiology and Pharmacology, School of Medicine, Qom University of Medical Sciences, Qom, Iran

Source: Archives of Endocrinology and Metabolism Published:2023


Abstract

Objective: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease and a growing global epidemic. In NAFLD, liver fat surpasses 5% of hepatocytes without the secondary causes of lipid accumulation or excessive alcohol consumption. Given the link between NAFLD and insulin resistance, the possible association between the rs2854744 (-202 G>T) promoter polymorphism of insulin-like growth factor binding protein 3 (IGFBP3) gene and NAFLD was investigated in this study. Materials and methods: In this genetic case-control association study, the IGFBP3 rs2854744 genotypes of 315 unrelated individuals, including 156 patients with biopsy-proven NAFLD and 159 controls, were determined using polymerase chain reaction/restriction fragment length polymorphism analyses. Results: The “GT+TT” genotype of the IGFBP3 rs2854744 polymorphism, compared with the ‘‘GG’’ genotype, was associated with a 2.7-fold increased risk of NAFLD after adjustment for confounding factors (P = 0.009; odds ratio [OR] = 2.71; 95% confidence interval [CI] = 1.19-3.18). Additionally, the IGFBP3 rs2854744 “T” allele, in comparison with the ‘‘G’’ allele, was significantly overrepresented in NAFLD patients than the controls (P = 0.008; OR = 1.85; 95%CI = 1.23-2.94). Conclusion: Our findings first indicated that the IGFBP3 rs2854744 “GT+TT” genotype is a marker of increased NAFLD susceptibility; however, it needs to be supported by further investigations in other populations. © 2023, Sociedade Brasileira de Endocrinologia e Metabologia. All rights reserved.
Experts (# of related papers)
Other Related Docs